Navigation Links
MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
Date:12/20/2011

ROCKVILLE, Md., Dec. 20, 2011 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, announced today that it will receive a milestone payment from Boehringer Ingelheim.  The milestone payment was triggered as part of an agreement executed in October 2010 to discover, develop and commercialize antibody-based therapeutics based on MacroGenics' Dual-Affinity Re-Targeting (DART) platform.  The amount of the milestone payment remained undisclosed.  Therapeutics in the global alliance will be directed against up to ten combinations of molecular targets and may span multiple therapeutic areas, including immunology, oncology, respiratory, cardiometabolic and infectious diseases.  To date, MacroGenics has achieved five pre-clinical milestones across both of its DART collaborations with Boehringer Ingelheim and Pfizer, Inc.

Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics, commented: "We are very encouraged by the progress we've made with this DART candidate in collaboration with Boehringer Ingelheim."  Dr. Koenig continued, "MacroGenics expects to advance multiple product candidates from this alliance in 2012 and beyond."

About MacroGenics
MacroGenics is a private, venture-backed biotechnology company that focuses on the discovery, development and delivery to patients of novel biologics for cancer, autoimmune disorders and infectious diseases. The company has built a fully-integrated set of capabilities in antibody-based product development which supports its innovative pipeline of clinical stage product candidates. MacroGenics' proprietary research is based on three core technology platforms, which include: (1) a leading research capability for screening and targeting cancer stem-like cells; (2) Dual-Affinity Re-Targeting (or DART) bispecific technology, which allows the incorporation of multiple specificities within a single recombinant molecule; and (3) Fc optimization, which enhances antibody-dependent effector functions.  The company has research and development collaborations with multiple, major pharmaceutical companies including Boehringer Ingelheim, Les Laboratoires Servier and Pfizer, Inc.  For more information about MacroGenics, please visit www.macrogenics.com.

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as MacroGenics' ability to raise additional capital, and risks related to its ability to initiate, and enroll patients in, planned clinical trials. You should not place undue reliance on any forward-looking statements. MacroGenics assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law.

 

 

 


'/>"/>
SOURCE MacroGenics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. MacroGenics Initiates Phase I Clinical Trial of MGAH22 for Patients With HER2-Expressing Solid Tumors
2. MacroGenics Enters Global Research Collaboration and License Agreement with Pfizer
3. MacroGenics Receives NIH Grant Funding of $9.8M for Three Projects; Funding Further Advances DART Platform and Infectious Disease Portfolio
4. MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus
5. Paulo F. Costa Joins MacroGenics Board of Directors
6. MacroGenics Appoints New Vice President of Business Development
7. MacroGenics Raises $25M in Series D-2 Financing
8. Life Technologies Ion Personal Genome Machine Receives San Diegos CONNECT Most Innovative New Product Award
9. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
10. Watsons Generic Yaz(R) Receives FDA Approval
11. UCSB professor receives award for graphene electronics research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2019)... ... 02, 2019 , ... Leading Regenerative Veterinary Medicine company, VetStem Biopharma , ... The film focuses on regenerative veterinary medicine as a means of improving the ... included in the Brentwood and Pacific Palisades International Film Festival in Los Angeles, ...
(Date:6/18/2019)... ... June 17, 2019 , ... IVERIC bio, Inc. (NASDAQ: ... for production and manufacturing of GMP-grade adeno-associated virus (AAV) vector for IVERIC bio’s ... pigmentosa (RHO-adRP) and IC-200 for the treatment of BEST1 related retinal diseases. IVERIC ...
(Date:6/12/2019)... ... June 12, 2019 , ... Leak Detection Associates (LDA), ... Pharmaceutical, Biotechnology, Medical Device and Food Packaging Industries, is excited to announce that ... grant exclusive rights for Zillion to represent LDA in all of China. ...
(Date:6/11/2019)... ... June 10, 2019 , ... Advancements ... an upcoming episode, scheduled to broadcast 4Q/2019. Check your local listings for more ... educate viewers about how its technology facilitates laboratories to improve efficiency and quality ...
Breaking Biology Technology:
(Date:6/27/2019)... , ... June 27, 2019 , ... Lighting designers from ... Energy Society (IES), which honored the designers for creating both engaging and energy efficient ... 701B Street , an office tower in San Diego, California earned an IES Illumination ...
(Date:6/19/2019)... , ... June 19, 2019 , ... Dahryn Trivedi, today ... properties of Cefazolin Sodium, antibiotic which can prove to be beneficial for treating multiple ... increase in residue amount , Over 68% decrease in weight , ...
(Date:6/14/2019)... ... 14, 2019 , ... Molecular diagnostics segment is the fastest-growing segment within the ... Major segments that are expected to drive the growth are infectious diseases, cancer, ... segments in Kalorama’s The World Molecular Diagnostics Market, 8th Edition . , The ...
Breaking Biology News(10 mins):